Masimo Corp

Masimo Corporation (ticker: MASI) develops non‑invasive monitoring technologies and patient‑monitoring systems used in hospitals, ambulatory settings and by consumers. Its product range includes advanced pulse oximetry sensors, monitoring platforms and software that aggregate physiological data for clinicians, alongside newer efforts in wearable and home monitoring. Revenue comes from device sales, sensors and recurring consumables, and software services; the company emphasises R&D and intellectual property as competitive assets. With a market capitalisation around $8.06 billion, Masimo sits among mid‑cap medical‑technology names and faces competition from larger equipment makers and emerging digital-health firms. Key considerations for investors include sensitivity to hospital procurement cycles, regulatory approvals, and potential litigation or patent disputes — all of which can affect results. Masimo’s business can offer exposure to healthcare’s structural demand for monitoring, but performance may be volatile; this summary is educational only, not personalised investment advice, and prospective investors should consider risk tolerance and seek professional guidance.